3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine | 135974-57-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
• 英文别名: 9-bromo-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol
• CAS: 135974-57-1
• 化学式: C₁₉H₂₀BrNO₂
• 分子量: 374.3
• InChiKey: KKZGFVAZUKHFAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• DNA REGULATORY ELEMENT FOR THE EXPRESSION OF TRANSGENES IN NEURONS OF THE MOUSE FOREBRAIN
  申请人：——

  公开号：US20010018207A1

  公开（公告）日：2001-08-30

  The present invention provides for a recombinant nucleic acid molecule comprising a region of a calcium-calmodulin dependent kinase II&agr; promoter operatively linked to a gene of interest. The region of a calcium-calmodulin dependent kinase II&agr; promoter may comprise an 8.5 kilobase nucleic acid sequence which corresponds to the nucleic acid sequence of ATCC Accession No. ______ , designated pMM281. The present invention also provides a human cell line which has been stably transformed by a recombinant nucleic acid molecule comprising a gene of interest operatively linked to a nucleic acid encoding a calcium-calmodulin dependent kinase II&agr; promoter region which has a nucleotide sequence corresponding to the sequence of ATCC Accession No. ______ designated pMM281. The present invention also provides for a transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII&agr; promoter (ATCC Accession No. ______ ), introduced into the mammal, or an ancestor thereof, at an embryonic stage. Another embodiment of the present invention is a method of evaluating whether a compound is effective in treating symptoms of a neurological disorder in a subject which comprises: (a) administering the compound to the transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII&agr; promoter, and(b) comparing the neurological function the mammal in step (a) with neurological function of the transgenic mammal in the absence of the compound, thereby determining whether the compound is effective in treating symptoms of the neurological disorder in a subject.

  本发明提供了一种重组核酸分子，该分子包含与相关基因操作性连接的钙钙调蛋白依赖性激酶 II&agr; 启动子区域。钙钙调蛋白依赖性激酶 II&agr;启动子区域可包括一个 8.5 千碱基的核酸序列，该序列与 ATCC 编号 ______ 的核酸序列相对应，命名为 pMM281。本发明还提供了一种人细胞系，该细胞系已被重组核酸分子稳定转化，该重组核酸分子包含与编码钙钙调蛋白依赖性激酶 II&agr; 启动子区域的核酸操作性连接的感兴趣基因，该启动子区域具有与 ATCC 登录号 ______ 的核苷酸序列相对应的序列，指定为 pMM281。本发明还提供了一种转基因非人类哺乳动物，其生殖细胞或体细胞含有在 CaMKII&agr; 启动子（ATCC登录号：______ ）控制下编码感兴趣基因的核酸分子，在胚胎阶段导入哺乳动物或其祖先体内。本发明的另一个实施方案是一种评估化合物是否能有效治疗受试者神经紊乱症状的方法，该方法包括：(a) 向转基因非人类哺乳动物施用化合物，该哺乳动物的生殖细胞或体细胞含有核酸分子，该核酸分子在 CaMKII&agr; 启动子的控制下编码感兴趣的基因；(b) 将步骤(a)中哺乳动物的神经功能与转基因哺乳动物在不施用化合物情况下的神经功能进行比较，从而确定化合物是否能有效治疗受试者的神经紊乱症状。
• MEDTHODS FOR IMPROVING LONG-TERM MEMORY STORAGE AND RETRIEVAL
  申请人：——

  公开号：US20020129385A1

  公开（公告）日：2002-09-12

  The present invention provides for a transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes calcineurin or a variant thereof under the control of a regulatable promoter, introduced into the mammal, or an ancestor thereof, at an embryonic stage. The present invention also provides for a method of evaluating whether a compound is effective in improving long-term memory in a subject suffering from impaired long-term memory which comprises: (a) administering the compound to the transgenic nonhuman mammal of claim 1 wherein the mammal has increased brain-specific calcineurin activity due to expression of the nucleic acid, and (b) comparing the long-term memory of the mammal in step (a) with the long-term memory of the mammal in the absence of the compound so as to determine whether the compound is effective in rescuing the long-term memory defect in the subject.

  本发明提供了一种转基因非人类哺乳动物，其生殖细胞或体细胞含有在可调节启动子控制下编码钙调素或其变体的核酸分子，该核酸分子在胚胎阶段被导入哺乳动物或其祖先体内。本发明还提供了一种评估化合物是否能有效改善长期记忆受损者的长期记忆的方法，该方法包括：(a) 给权利要求 1 的转基因非人哺乳动物施用化合物，其中哺乳动物因表达核酸而增加了脑特异性钙调素活性；以及 (b) 将步骤(a)中哺乳动物的长时记忆与未施用化合物时哺乳动物的长时记忆进行比较，以确定化合物是否能有效挽救受试者的长时记忆缺陷。
• Transgenic mammals and reagents for improving long-term memory
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20030140360A1

  公开（公告）日：2003-07-24

  The present invention provides for a transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes calcineurin or a variant thereof under the control of a regulatable promoter, introduced into the mammal, or an ancestor thereof, at an embryonic stage. The present invention also provides for a method of evaluating whether a compound is effective in improving long-term memory in a subject suffering from impaired long-term memory which comprises: (a) administering the compound to the transgenic nonhuman mammal of claim 1 wherein the mammal has increased brain-specific calcineurin activity due to expression of the nucleic acid, and (b) comparing the long-term memory of the mammal in step (a) with the long-term memory of the mammal in the absence of the compound so as to determine whether the compound is effective in rescuing the long-term memory defect in the subject.

  本发明提供了一种转基因非人类哺乳动物，其生殖细胞或体细胞含有在可调节启动子控制下编码钙调素或其变体的核酸分子，该核酸分子在胚胎阶段被导入哺乳动物或其祖先体内。本发明还提供了一种评估化合物是否能有效改善长期记忆受损者的长期记忆的方法，该方法包括：(a) 给权利要求 1 的转基因非人哺乳动物施用化合物，其中哺乳动物因表达核酸而增加了脑特异性钙调素活性；以及 (b) 将步骤(a)中哺乳动物的长时记忆与未施用化合物时哺乳动物的长时记忆进行比较，以确定化合物是否能有效挽救受试者的长时记忆缺陷。
• Treatment of anhedonia
  申请人：Nathanson L. Donald

  公开号：US20060217394A1

  公开（公告）日：2006-09-28

  A therapeutic method for the enhancement of mood in patients afflicted with iatrogenic anhedonia secondary to chronic increases in the availability and/or efficiency of serotonin, with or without increases in the availability and/or efficiency of norepinephrine.

  一种治疗方法，用于改善因长期增加血清素的供应量和/或效率，同时或不增加去甲肾上腺素的供应量和/或效率而继发的先天性失神症患者的情绪。
• Methods and reagents for dendritic localization of polynucleotides
  申请人：——

  公开号：US20040009497A1

  公开（公告）日：2004-01-15

  The present invention provides for a recombinant nucleic acid molecule comprising a region of a calcium-calmodulin dependent kinase II&agr; promoter operatively linked to a gene of interest. The region of a calcium-calmodulin dependent kinase II&agr; promoter may comprise an 8.5 kilobase nucleic acid sequence which corresponds to the nucleic acid sequence of ATCC Accession No. ______, designated pMM281. The present invention also provides a human cell line which has been stably transformed by a recombinant nucleic acid molecule comprising a gene of interest operatively linked to a nucleic acid encoding a calcium-calmodulin dependent kinase II&agr; promoter region which has a nucleotide sequence corresponding to the sequence of ATCC Accession No. ______, designated pMM281. The present invention also provides for a transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII&agr; promoter (ATCC Accession No. ______), introduced into the mammal, or an ancestor thereof, at an embryonic stage. Another embodiment of the present invention is a method of evaluating whether a compound is effective in treating symptoms of a neurological disorder in a subject which comprises: (a) administering the compound to the transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII&agr; promoter, and (b) comparing the neurological function the mammal in step (a) with neurological function of the transgenic mammal in the absence of the compound, thereby determining whether the compound is effective in treating symptoms of the neurological disorder in a subject.